

Supplement Table 2. Baseline cancer status of the study population

Variable	Total (n=122)	ADT+abiraterone (n=102)	ADT+docetaxel (n=20)	p-value
PSA at initial diagnosis (ng/mL)	142.7 (54.7–626.3)	150.0 (55.5–651.0)	100.0 (52.7–604.7)	0.596
PSA at metastasis (ng/mL)	151.6 (57.4–626.3)	161.6 (62.6–664.8)	86.0 (44.2–500.0)	0.292
Testosterone at metastasis (ng/mL)	3.3 (2.6–4.8)	3.7 (2.7–5.7)	2.8 (2.6–3.4)	0.192
Clinical tumor stage				0.083
≤T3a	16 (13.1)	10 (9.8)	6 (30.0)	
T3b	42 (34.4)	36 (35.3)	6 (30.0)	
T4	59 (48.4)	51 (50.0)	8 (40.0)	
Unknown	5 (5.1)	5 (4.9)	0 (0.0)	
ECE				0.834
No	5 (5.1)	4 (3.9)	1 (5.0)	
Yes	103 (84.4)	87 (85.3)	16 (80.0)	
Unknown	14 (11.5)	11 (10.8)	3 (15.0)	
SVI				0.166
No	16 (13.1)	11 (10.8)	5 (25.0)	
Yes	92 (75.4)	80 (78.4)	12 (60.0)	
Unknown	14 (11.5)	11 (10.8)	3 (15.0)	
Gleason score				0.695
≤8	60 (49.2)	51 (50.0)	9 (45.0)	
≥9	59 (48.4)	49 (48.0)	10 (50.0)	
Unknown	3 (2.5)	2 (2.0)	1 (5.0)	
No. of positive cores	8.0 (6.0–12.0)	8.0 (6.0–12.0)	10.0 (5.0–12.5)	0.605
No. of total cores	12.0 (12.0–12.0)	12.0 (12.0–12.0)	12.0 (6.0–14.0)	0.525
% Of positive cores	91.7 (60.7–100.0)	90.3 (58.3–100.0)	95.8 (71.1–100.0)	0.215
Max. rate (%)	90.0 (75.0–100.0)	90.0 (75.0–100.0)	91.9 (80.6–100.0)	0.285

Values are presented as medians (interquartile ranges) or numbers (%), unless otherwise indicated.

ECE: extracapsular extension, PSA: prostate-specific antigen, SVI: seminal vesicle invasion, Max: maximum.